英文别名3-(2-((2-Methyl-5-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)phenyl)amino)pyrimidin-4-yl)pyridine 1-oxide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(1-oxidopyridin-1-ium-3-yl)pyrimidin-2-yl]amino]benzamide; BEJ-866; Nilotinib metabolite P36; BEJ866; Nilotinib Impurity 10; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl-N-oxide)-2-pyrimidinyl)amino)benzamide; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(1-oxido-3-pyridinyl)-2-pyrimidinyl)amino)-; 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(1-oxo-1lambda~5~-pyridin-3-yl)pyrimidin-2-yl]amino}benzamide; Nilotinib N-Oxide Impurity 2; Nilotinib N-Oxide Impurity 
